Herbert Kuhl

Last updated
Herbert Kuhl
Photo of gynecologist Herbert Kuhl from a 1999 publication.png
A photo of Kuhl taken from a 1999 paper [1]
Born1940 (age 82–83)
Aschaffenburg, Germany
Nationality German
Education Goethe University Frankfurt: chemistry and biochemistry (1961–1967); doctorate in biochemistry and pharmacy (1972); postdoctoral qualification in human medicine for the subject of experimental endocrinology (1977) [1]
Occupation(s) Gynecologist; Medical researcher
Years active1970 [2] –present
Medical career
ProfessionProfessor, physician
InstitutionsDepartment of Obstetrics and Gynecology, J. W. Goethe University of Frankfurt; Universitäts-Frauenklinik in Frankfurt
Research Gynecology

Herbert Kuhl is a German gynecologist who has published extensively in the areas of estrogens, progestogens, menopause, hormonal contraception, and menopausal hormone therapy. [1] His works include numerous original and review articles and several books. [1] Kuhl is a member of many medical societies and has received various scientific awards. [1]

Contents

Among Kuhl's most widely cited publications is his 2005 literature review in the journal Climacteric , Pharmacology of Estrogens and Progestogens: Influence of Different Routes of Administration. [3] [4] He has published several articles interpreting the findings of the Women's Health Initiative (WHI) study. [5] [6] [7] [8] [9] [10] [11]

Kuhl was born in Aschaffenburg, Germany in 1940. [1] He was educated at the Goethe University Frankfurt from 1961 to 1977. [1] Kuhl first published in 1970. [2] From 1981, he was a professor at the Universitäts-Frauenklinik (University Women's Clinic) of the Goethe University Frankfurt. [5] Until 2013, Kuhl continued to be affiliated with this institution. [11] Since then however, he has listed no affiliation in his publications except that he resides in Aschaffenburg, Germany. [12] [13]

Selected publications

Books

Authored books

  • Kuhl, Herbert; Taubert, Hans-Dieter (1987). Das Klimakterium – Pathophysiologie, Klinik, Therapie[The Climacteric – Pathophysiology, Clinic, Therapy] (in German). Stuttgart, Germany: Thieme Verlag. ISBN   978-3137008019. OCLC   19780387. OL   31949169M. (1st and only edition)
  • Hans-Dieter Taubert; Herbert Kuhl (1995). Kontrazeption mit Hormonen: ein Leitfaden für die Praxis [Hormonal Contraception: A Practical Guide] (in German) (2 ed.). Stuttgart, Germany: Thieme. ISBN   978-3-13-608802-9. OCLC   1068026728. (1st edition published in 1981)
  • Herbert Kuhl; Claudia Jung-Hoffman (1999). Kontrazeption[Contraception] (in German) (2 ed.). Georg Thieme Verlag. ISBN   978-3131179920. OCLC   237359985. OL   12671120M. (1st edition published in 1996)
  • Kuhl, Herbert; Wiegratz, Inka (1 January 2008). Klimakterium, Postmenopause und Hormonsubstitution [Climacteric, Postmenopause and Hormone Replacement] (in German) (4 ed.). UNI-MED-Verlag. ISBN   978-3-83742-043-2. OCLC   553736917. OL   31949179M. (Earlier editions published in 1999 (1st), 2001 (2nd), and 2005/2006 (3rd))
  • Inka Wiegratz; Herbert Kuhl (2010). Langzyklus [Long Cycle] (in German). Georg Thieme Verlag. ISBN   978-3-13-153301-2. OCLC   649505497. (1st and only edition)

Edited books

Book chapters

Journal articles

Reviews

Studies

Theses/dissertations

Related Research Articles

<span class="mw-page-title-main">Progestogen (medication)</span> Medication producing effects similar to progesterone

A progestogen, also referred to as a progestagen, gestagen, or gestogen, is a type of medication which produces effects similar to those of the natural female sex hormone progesterone in the body. A progestin is a synthetic progestogen. Progestogens are used most commonly in hormonal birth control and menopausal hormone therapy. They can also be used in the treatment of gynecological conditions, to support fertility and pregnancy, to lower sex hormone levels for various purposes, and for other indications. Progestogens are used alone or in combination with estrogens. They are available in a wide variety of formulations and for use by many different routes of administration. Examples of progestogens include natural or bioidentical progesterone as well as progestins such as medroxyprogesterone acetate and norethisterone.

<span class="mw-page-title-main">Estradiol valerate</span> Chemical compound

Estradiol valerate (EV), sold for use by mouth under the brand name Progynova and Primiwal E4 and for use by injection under the brand names Delestrogen and Progynon Depot among others, is an estrogen medication. It is used in hormone therapy for menopausal symptoms and low estrogen levels, hormone therapy for transgender people, and in hormonal birth control. It is also used in the treatment of prostate cancer. The medication is taken by mouth or by injection into muscle or fat once every 1 to 4 weeks.

<span class="mw-page-title-main">Drospirenone</span> Medication drug

Drospirenone is a progestin and antiandrogen medication which is used in birth control pills to prevent pregnancy and in menopausal hormone therapy, among other uses. It is available both alone under the brand name Slynd and in combination with an estrogen under the brand name Yasmin among others. The medication is an analog of the drug spironolactone. Drospirenone is taken by mouth.

<span class="mw-page-title-main">Norethisterone acetate</span> Chemical compound

Norethisterone acetate (NETA), also known as norethindrone acetate and sold under the brand name Primolut-Nor among others, is a progestin medication which is used in birth control pills, menopausal hormone therapy, and for the treatment of gynecological disorders. The medication available in low-dose and high-dose formulations and is used alone or in combination with an estrogen. It is ingested orally.

<span class="mw-page-title-main">Norgestrel</span> Pair of enantiomers

Norgestrel, sold under the brand name Ovral among others, is a progestin medication which is used in birth control pills and in menopausal hormone therapy. It is available both in combination with an estrogen and alone. It is taken by mouth.

<span class="mw-page-title-main">Tibolone</span> Chemical compound

Tibolone, sold under the brand name Livial among others, is a medication which is used in menopausal hormone therapy and in the treatment of postmenopausal osteoporosis and endometriosis. The medication is available alone and is not formulated or used in combination with other medications. It is taken by mouth.

<span class="mw-page-title-main">Norethisterone</span> Progestin medication

Norethisterone, also known as norethindrone and sold under many brand names, is a progestin medication used in birth control pills, menopausal hormone therapy, and for the treatment of gynecological disorders. The medication is available in both low-dose and high-dose formulations and both alone and in combination with an estrogen. It is used by mouth or, as norethisterone enanthate, by injection into muscle.

<span class="mw-page-title-main">Gestodene</span> Progestin medication

Gestodene, sold under the brand names Femodene and Minulet among others, is a progestin medication which is used in birth control pills for women. It is also used in menopausal hormone therapy. The medication is available almost exclusively in combination with an estrogen. It is taken by mouth.

<span class="mw-page-title-main">Lynestrenol</span> Androgen and anabolic steroid

Lynestrenol, sold under the brand names Exluton and Ministat among others, is a progestin medication which is used in birth control pills and in the treatment of gynecological disorders. The medication is available both alone and in combination with an estrogen. It is taken by mouth.

<span class="mw-page-title-main">Ethisterone</span> Chemical compound

Ethisterone, also known as ethinyltestosterone, pregneninolone, and anhydrohydroxyprogesterone and formerly sold under the brand names Proluton C and Pranone among others, is a progestin medication which was used in the treatment of gynecological disorders but is now no longer available. It was used alone and was not formulated in combination with an estrogen. The medication is taken by mouth.

<span class="mw-page-title-main">Mestranol</span> Chemical compound

Mestranol, sold under the brand names Enovid, Norinyl, and Ortho-Novum among others, is an estrogen medication which has been used in birth control pills, menopausal hormone therapy, and the treatment of menstrual disorders. It is formulated in combination with a progestin and is not available alone. It is taken by mouth.

<span class="mw-page-title-main">Dienogest</span> Chemical compound

Dienogest, sold under the brand name Visanne among others, is a progestin medication which is used in birth control pills and in the treatment of endometriosis. It is also used in menopausal hormone therapy and to treat heavy periods. Dienogest is available both alone and in combination with estrogens. It is taken by mouth.

Hormone replacement therapy (HRT), also known as menopausal hormone therapy or postmenopausal hormone therapy, is a form of hormone therapy used to treat symptoms associated with female menopause. These symptoms can include hot flashes, vaginal atrophy, accelerated skin aging, vaginal dryness, decreased muscle mass, sexual dysfunction, and bone loss or osteoporosis. They are in large part related to the diminished levels of sex hormones that occur during menopause.

<span class="mw-page-title-main">Estradiol benzoate</span> Chemical compound

Estradiol benzoate (EB), sold under the brand name Progynon-B among others, is an estrogen medication which is used in hormone therapy for menopausal symptoms and low estrogen levels in women, in hormone therapy for transgender women, and in the treatment of gynecological disorders. It is also used in the treatment of prostate cancer in men. Estradiol benzoate is used in veterinary medicine as well. When used clinically, the medication is given by injection into muscle usually two to three times per week.

<span class="mw-page-title-main">Estriol succinate</span> Chemical compound

Estriol succinate, sold under the brand name Synapause among others, is an estrogen medication which is used in the treatment of menopausal symptoms. It is taken by mouth, in through the vagina, and by injection.

<span class="mw-page-title-main">Trimegestone</span> Chemical compound

Trimegestone, sold under the brand names Ondeva and Totelle among others, is a progestin medication which is used in menopausal hormone therapy and in the prevention of postmenopausal osteoporosis. It was also under development for use in birth control pills to prevent pregnancy, but ultimately was not marketed for this purpose. The medication is available alone or in combination with an estrogen. It is taken by mouth.

<span class="mw-page-title-main">Nomegestrol acetate</span> Chemical compound

Nomegestrol acetate (NOMAC), sold under the brand names Lutenyl and Zoely among others, is a progestin medication which is used in birth control pills, menopausal hormone therapy, and for the treatment of gynecological disorders. It is available both alone and in combination with an estrogen. NOMAC is taken by mouth. A birth control implant for placement under the skin was also developed but ultimately was not marketed.

<span class="mw-page-title-main">Estradiol (medication)</span> Steroidal hormone medication

Estradiol (E2) is a medication and naturally occurring steroid hormone. It is an estrogen and is used mainly in menopausal hormone therapy and to treat low sex hormone levels in women. It is also used in hormonal birth control for women, in hormone therapy for transgender women, and in the treatment of hormone-sensitive cancers like prostate cancer in men and breast cancer in women, among other uses. Estradiol can be taken by mouth, held and dissolved under the tongue, as a gel or patch that is applied to the skin, in through the vagina, by injection into muscle or fat, or through the use of an implant that is placed into fat, among other routes.

<span class="mw-page-title-main">Estrogen (medication)</span> Type of medication

An estrogen (E) is a type of medication which is used most commonly in hormonal birth control and menopausal hormone therapy, and as part of feminizing hormone therapy for transgender women. They can also be used in the treatment of hormone-sensitive cancers like breast cancer and prostate cancer and for various other indications. Estrogens are used alone or in combination with progestogens. They are available in a wide variety of formulations and for use by many different routes of administration. Examples of estrogens include bioidentical estradiol, natural conjugated estrogens, synthetic steroidal estrogens like ethinylestradiol, and synthetic nonsteroidal estrogens like diethylstilbestrol. Estrogens are one of three types of sex hormone agonists, the others being androgens/anabolic steroids like testosterone and progestogens like progesterone.

<span class="mw-page-title-main">Estradiol valerate/prasterone enanthate</span> Combination drug

Estradiol valerate/prasterone enanthate (EV/DHEA-E), sold under the brand name Gynodian Depot among others, is an injectable combination medication of estradiol valerate (EV), an estrogen, and prasterone enanthate (DHEA-E), an androgen, estrogen, and neurosteroid, which is used in menopausal hormone therapy for women. It is provided in the form of 1 mL ampoules containing 4 mg estradiol valerate and 200 mg prasterone enanthate in an oil solution and is administered by intramuscular injection once every 4 to 6 weeks. EV/DHEA-E reportedly has a duration of about 21 days.

References

  1. 1 2 3 4 5 6 7 Kuhl H (1999). "Östrogene für den Mann?" [Estrogens for the Man?]. Journal für Menopause [Ausgabe für Österreich]. 6 (2): 15–23. ISSN   1025-6873.
  2. 1 2 Taubert, H.-D.; Heil, H.; Kuhl, H. (1970). "Untersuchungen über die Wirkung von Äthynil-Oestradiol auf die L-Cystin-Aminopeptidosen-Aktivität im Hypothalamus der weiblichen Ratte" [Investigations on the Effect of Ethynil-Oestradiol on L-Cystine-amino-peptidase Activity in the Hypothalamus of Female Rats]. In Kracht, Joachim (ed.). Endokrinologie der Entwicklung und Reifung: 16. Symposion, Ulm, 26.-28. Februar 1970. Symposion der Deutschen Gesellschaft für Endokrinologie. Vol. 16. Berlin/Heidelberg/New York: Springer-Verlag. pp. 288–289. doi:10.1007/978-3-642-80591-2. ISBN   978-3-642-80591-2. OCLC   863921711.
  3. ↑ Kuhl, H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. eISSN   1473-0804. ISSN   1369-7137. PMID   16112947. S2CID   24616324.
  4. ↑ "Web of Science". Clarivate. Retrieved 19 August 2022.
  5. 1 2 Kuhl H (2003). "Die unterschätzte Bedeutung der Gestagene bei der Hormonsubstitution" [The Underestimated Importance of Progestins in Hormone Replacement Therapy]. Journal für Menopause [Ausgabe für Österreich]. 10 (3): 6–12. ISSN   1025-6873.
  6. ↑ Wiegratz I, Kuhl H (August 2004). "Progestogen therapies: differences in clinical effects?". Trends Endocrinol Metab. 15 (6): 277–85. doi:10.1016/j.tem.2004.06.006. PMID   15358281. S2CID   35891204.
  7. ↑ Mueck, A. O.; Kuhl, H.; Braendle, W. (September 2004). "Ergebnisse und Kommentare zu der WHI-Studie mit Estrogen-Monotherapie" [Results of and Comments on the WHI Study with Estrogen Monotherapy]. Geburtshilfe und Frauenheilkunde (in German). 64 (9): 917–922. doi:10.1055/s-2004-821217. eISSN   1438-8804. ISSN   0016-5751. S2CID   71579060.
  8. ↑ Kuhl H (September 2004). "Is the elevated breast cancer risk observed in the WHI study an artifact?". Climacteric. 7 (3): 319–22. doi:10.1080/13697130400003337. PMID   15669557.
  9. ↑ Kuhl H (May 2005). "Breast cancer risk in the WHI study: the problem of obesity". Maturitas. 51 (1): 83–97. doi:10.1016/j.maturitas.2005.02.018. PMID   15883113.
  10. ↑ Kuhl H, Stevenson J (June 2006). "The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results". Gynecol Endocrinol. 22 (6): 303–17. doi:10.1080/09513590600717368. PMID   16785155. S2CID   25260381.
  11. 1 2 Kuhl, H.; Schneider, H. P. G. (20 February 2013). "Progesterone – promoter or inhibitor of breast cancer". Climacteric. 16 (Suppl 1): 54–68. doi:10.3109/13697137.2013.768806. eISSN   1473-0804. ISSN   1369-7137. PMID   23336704. S2CID   20808536.
  12. ↑ Kuhl, Herbert; Wiegratz, Inka (10 April 2017). "Das Post-Finasterid-Syndrom" [Post-finasteride syndrome]. Gynäkologische Endokrinologie (in German). 15 (2): 153–163. doi:10.1007/s10304-017-0126-2. eISSN   1610-2908. ISSN   1610-2894. S2CID   207071180.
  13. ↑ Kuhl, H.; Wiegratz, I. (1 February 2021). "Pharmakokinetik und Pharmakodynamik der in der assistierten Reproduktion verwendeten Gestagene" [Pharmacokinetics and pharmacodynamics of progestogens used in assisted reproduction]. Gynäkologische Endokrinologie (in German). 19 (2): 105–117. doi:10.1007/s10304-020-00372-5. eISSN   1610-2908. ISSN   1610-2894. S2CID   231744549.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.